Founded in 1999, PELVIPHARM is a spin-off from the University of Versailles-Saint-Quentin-en-Yvelines (France) relying on multi-disciplinary talents (medical doctor, pharmaco-economist, veterinarian, pharmacists and PhDs) who deliver both high quality academic standards and reliable contract research services :
- Preclinical studies based on validated efficacy models including delivery of protocol development, study conduct, report, communication and peer-reviewed publication
- Guidance for selection of new chemical entities including testing with targeted assays according to potential mechanisms of action
- Identification of new properties or attributes supporting differentiation of medications within the class or between classes
- Advice in clinical development for new therapeutic indications or enhancements to address unmet medical need or significant commercial opportunities
PELVIPHARM has leading scientific and medical capabilities from unique expertise and experience in pathophysiology, pharmacology, clinical research and medical practice across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC …), sexual medicine (ED, PE, FSD …) and cardiovascular (Hypertension, Atherosclerosis, Myocardial Infarction …), metabolism and eating disorders (Metabolic Syndrome, Obesity, Diabetes ...)
PELVIPHARM can give you the unique expertise and the experience of a team gathered over the years.
News and next meetings
Pelvipharm presented 1 abstract at the American Diabetes Association in Boston, MA, USA, June 5-9, 2......
Future presentations at the AUA 2015
Pelvipharm presented 2 abstracts at the American Urological Association in New Orleans, LA, USA, May......
François Giuliano : president elect of the ESSM
On february 6th 2015, François Giuliano became the president elect of the European Society for Sexua......
Publication in Neurology of Sexual and Bladder Disorders
Anatomy and physiology of genital organs – men Clément P. and Giuliano F. 2015: Vol.130 - ch.3 Ed......
Latest website updates
New abstract/poster available for download
Does reduction of number injection sites of abobotulinum toxin A impact efficacy in Neurogenic Detrusor Overactivity (NDO) in the spinal cord-injured (SCI) rat model?
presented at Toxins 2015 in Lisbon,
Portugal, 14-17 january, 2015
New experimental skills developed
New model developped